Tag: SynNic

  • E-LiquiTech Confirms Available Stock of Synthetic Nicotine

    E-LiquiTech Confirms Available Stock of Synthetic Nicotine

    Credit: TTI

    E-LiquiTech says it has large quantities of Zanoprima’s SyNic in stock to help companies introduce new products to the U.S. market ahead of the mid-April deadline imposed by a new law.

    On March 15, 2022, President Joe Biden signed into law a spending bill that includes a provision to regulate products containing synthetic nicotine the same as products containing tobacco-derived nicotine. This means that companies selling products containing synthetic nicotine will be required to file a premarket tobacco product application in order to keep their product(s) on the market. The deadline for filing such applications is less than 60 days away.

    According to E-LiquiTech, SyNic is the same chemical composition of (S)-nicotine as natural tobacco-derived nicotine but without any of the impurities. Specifically, SyNic achieves a purity profile of 99.9 percent and is devoid of tobacco-specific nitrosamines, heavy metals and other impurities that are present in tobacco-derived nicotine.

    SyNic is manufactured through a patented process in a cGMP facility approved by the U.S. Food and Drug Administration and meets or exceeds the U.S. Pharmacopeia monograph, making SyNic a 1-to-1 replacement for tobacco-derived nicotine and enabling manufacturers to use it as a CAS number substitute, according to E-LiquiTech.

    The company says all of the scientific data that is applicable to tobacco-derived nicotine is equally applicable to SyNic. The manufacturing process is replicable from batch to batch, and every batch of SyNic is fully trackable and traceable.

    Earlier this month, Zanoprima filed a patent lawsuit against Hangsen International in the U.S. District Court for the Western District of Texas to enforce Zanoprima’s patented process for manufacturing (S)-nicotine, demonstrating its long-term commitment to the U.S. market.

  • Zanoprima Files Patent Violation Suit Against Hangsen

    Zanoprima Files Patent Violation Suit Against Hangsen

    A patent infringement lawsuit has been filed by Zanoprima Lifesciences against Hangsen International Group for infringement on Zanoprima’s patent to produce synthetic nicotine.

    Filed in the U.S. District Court in the Western District of Texas, Zanoprima claims Hangsen violated its patent entitled “Process for Making (S)-Nicotine” (U.S. Patent No. 10,913,962) and Hangsen has been importing products that include a a synthetic nicotine into the U.S. that is produced by using Zanoprima’s patent.

    “Over many years, Zanoprima has invested substantial time, resources, intellectual capital, and scientific expertise into developing Zanoprima’s groundbreaking enzymatic patented process for synthesizing an (S)-nicotine that is devoid of tobacco-specific nitrosamines and other impurities,” stated Ashok Narasimhan, CEO of Zanoprima, in a press release. “Zanoprima’s legal action reflects our company’s dedication to vigorously protecting our intellectual property in the U.S. and around the world.”

    The complaint alleges that, after publication of Zanoprima’s patent, Hangsen filed a Chinese patent application describing a process that copied the process invented by Zanoprima. However, as alleged in the complaint, Hangsen’s patent application was rejected by the Chinese Patent Office in June 2021 citing Zanoprima’s patent as prior art.

    The complaint also alleges Hangsen imports into the U.S. from China and sells products containing “alleged high-purity synthetic (S)-nicotine and nicotine products that are marketed and sold under various names including as MOTiVO Synthetic S-Nicotine,” and that such imported products “are manufactured by a process that practices every step … of the Zanoprima patent.”

    In addition to seeking damages for infringement, Zanoprima’s complaint seeks preliminary and permanent injunctive relief to prevent Hangsen from continuing infringing upon Zanoprima’s patent.

    Zanoprima is the first company to manufacture and make commercially available an enzymatically synthesized form of pure (S)-nicotine, SynNic, according to the release. The synthetic nicotine is chemically identical to that derived from tobacco but devoid of harmful tobacco-specific nitrosamines, carcinogens, alkaloids, and other impurities that accompany tobacco-derived nicotine.